Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rubone is a synthetic chalcone analog and **miR-34a modulator** that upregulates miR-34a expression in cancer cells, particularly in hepatocellular carcinoma cells, including those with wild-type or mutated p53. By increasing miR-34a, rubone impacts downstream gene expression including **downregulation of Bcl-2**, leading to antiproliferative and pro-apoptotic effects in tumor cells. It is primarily used in research and has no approved therapeutic indications. Mechanistically, rubone’s effect is dependent on p53 status, serving as a small molecule modulator of microRNA expression[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rubone.